Estimates on waste of breast cancer related chemotherapy drugs in the NHS (England)

Previous PostAssessing the definition and outcomes of innovative drugs by Health Technology Assessment bodies in England, France, and Italy (Q1 2023)
Next PostCost-effectiveness of difelikefalin for the treatment of moderate to severe chronic kidney disease-associated pruritus (CKD-aP) in adult patients receiving in-centre haemodialysis